EPHA3 and glioblastoma: An EphA3 monoclonal antibody (IIIA4) that binds the EphA3 globular ephrin-binding domain has been developed, and the humanised version (ifabotuzumab) is the subject of an investigator-sponsored Phase 0/1 clinical trial currently underway in patients with recurrent GBM (55) to identify the optimal dose for tumour penetration.